Pharmacia Corp. a future biotech powerhouse? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacia Corp. a future biotech powerhouse?

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Michael Kucera who wrote ()	5/24/2000 11:12:00 PM
From: Jack Hartmann	of 35

Pharmacia Corp: Parecoxib Sodium 'Superior' To Ketorolac Dow Jones Newswires SAN DIEGO -- Pharmacia Corp. (PHA) said parecoxib sodium was "superior" to ketorolac in a study of gastroduodenal effects of intravenous analgesics in the elderly. In a press release Wednesday, the company said ketorolac is the only injectable non-steroidal anti-inflammatory drug approved for use in the U.S., but parecoxib sodium was developed to provide the efficacy and safety of a COX-2 specific inhibitor in an injection formula. Parecoxib sodium was developed by Searle, which is now a part of Pharmacia Corp., which was created through the merger of Pharmacia & Upjohn with Monsanto Co. and its G.D. Searle unit. New York Stock Exchange-listed shares of Pharmacia were recently trading at 51 7/8 down 1 5/8, or 3%, on volume of 2.75 million shares. Average daily is 3.6 million shares. -Jason Philyaw; Dow Jones Newswires; 201-938-5388 ************* Despite the market turmoil, this one hangs above $50. Jack

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next